2nd World PGx Summit (PGX2)
Venue: Radisson Boston
|Event Date/Time: Apr 24, 2012||End Date/Time: Apr 26, 2012|
Not understanding variability in drug response amongst patients is currently themajor limiting factor in bringing new drugs to market. Using pharmacogenomics to explain this variation and predict patient outcomes is the key to accelerated drug discovery and development, risk reduction, regulatory drug approval and product differentiation.
But successfully implementing a PGx strategy to improve drug development is fraught with major difficulties that are currently preventing the widespread success of this strategy.
The 2nd World PGx Summit will once again bring together drug industry leaders and key technology providers to capitalize on the enormous opportunity to use molecular data to improve decision-making in drug development. From safety to efficacy, whole genome sequencing to transcriptomics, learn from industry leaders about the latest technology and methodology to explain variation in drug response and increase your drugâ€™s chance of success. View the draft agenda here.
Whatâ€™s on the agenda?
Building on the success of last yearâ€™s meeting, we have once again designed the agenda specifically to help you make the most out of molecular data to accelerate your drug development. Learn from drug industry leaders how to stratify patient populations with the right PGx approach and increase your drugâ€™s chance of success. Here are just some of the topics our experts will be addressing:
â€¢ How to build a PGx strategy into the whole drug development life-cycle: From drug discovery, to clinical development and post-marketing
â€¢ How to systematically evaluate the utility of a PGx approach for individual drug programs and identify the questions your PGx program should give answers to
â€¢ Understanding the role of high throughput omics technologies to explain variation in drug response, including whole genome sequencing
â€¢ Understanding the latest PGx advances across a range of therapeutic areas, including HCV, oncology, neuroscience and autoimmune disease
â€¢ How to accelerate early research, screen out unsuitable compounds and improve drug design in preclinical research using molecular analyses
â€¢ Stratifying patients to improve progression through the clinic by identifying predictors of drug efficacy and rare adverse events
â€¢ Understand the regulatory requirements for PGx in drug safety assessment, genomic clinical trials and companion diagnostic development
â€¢ When does a predictive marker in the clinic turn into a companion diagnostic? And how do you develop and commercialize a companion diagnostic based on a genomic marker?
These topics will form the core of this yearâ€™s agenda. Please view the agenda pages for more details.
How is the meeting different?
The focus of this meeting is on challenges drug developers are facing in integrating molecular profiling approaches into drug development. As a result we have more senior decision makers from drug developers on the agenda than any other meeting of itâ€™s kind.
If youâ€™re a drug developer: The agenda, speakers and contacts you will make at this meeting will allow you to develop a comprehensive PGx strategy into your drug development programs. The agenda will show you how your peers are overcoming the same challenges you are facing and the world leading technology developers will be in the same room to provide solutions.
If youâ€™re a technology or service provider: The focus on drug developer needs is perfect. It creates the perfect environment for you to network with key decision-makers. Drug developers committed to personalised medicine who are looking for solutions. Youâ€™ll find yourself having more conversations with drug developers that lead to the prospect of business. Youâ€™ll understand the needs of your principal target market. AND learn how your competitors are addressing the same issues you're facing.
By the way, if you work for any of the above company types and youâ€™re interested in speaking, you can contact us here.
Who will attend and why?
We have a wide-range of attendees from Vice Presidents and C-Level industry leaders, to Directors, Sector Heads and Scientists across a wide range of functions including:
â€¢ Molecular profiling
â€¢ Personalized medicine
â€¢ Translational medicine
â€¢ Clinical research and development
â€¢ Specimen management
â€¢ Portfolio and project management/strategy
â€¢ Business development
Whether you are new to the field or expanding your existing capabilities around sequencing technologies and pharmacogenomics strategy, this meeting is a one-stop shop of the latest developments and strategies you need to be aware of.
Register now to speak with leaders from the worldâ€™s most forward-thinking developers and start to capitalize on the huge opportunity of pharmacogenomics to deliver better, safer drugs to market.